BIOMAT Database Logo BIOMAT Database Logo

The human near-term myometrial beta 3-adrenoceptor but not the beta 2-adrenoceptor is resistant to desensitisation after sustained agonist stimulation. 2004

C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
UPRES EA220-Pharmacology, UFR Biomédicale des Saints Pères, 45 rue des Saints Pères, Paris 75006, France. celine.rouget@biomedicale.univ-paris5.fr

1. In order to compare the beta(2)- and beta(3)-adrenoceptor (beta-AR) desensitisation process in human near-term myometrium, we examined the influence of a pretreatment of myometrial strips with either a beta(2)- or a beta(3)-AR agonist (salbutamol or SR 59119A, respectively, both at 10 microm, for 5 and 15 h) on the relaxation and the cyclic adenosine monophosphate (cAMP) production induced by these agonists. 2. To assess some of the mechanisms potentially implicated in the beta-AR desensitisation process, we studied the influence of such treatment on the number of beta(2)- and beta(3)-AR binding sites, the beta(2)- and beta(3)-AR transcripts expression and the phosphodiesterase 4 (PDE4) activity. 3. Salbutamol, but not SR 59119A, concentration-response curve (CRC) was shifted by a 15 h salbutamol preincubation, with a significant difference in -log EC(20) values (6.31+/-0.13 vs 5.58+/-0.24, for control and 15 h salbutamol pretreatment, respectively, P<0.05). Neither salbutamol nor SR 59119A CRCs were modified after a 15 h preincubation with SR 59119A. 4. A 15 h exposure of myometrial strips to salbutamol significantly reduced the salbutamol-induced (0.60+/-0.26 vs 1.54+/-0.24 pmol mg(-1) protein, P<0.05), but not the SR 59119A-induced, cAMP production. No decrease in cAMP production was observed after a 15 h SR 59119A exposure. 5. A 15 h salbutamol exposure of myometrial strips significantly reduced the beta(2)- but not the beta(3)-AR binding site density, whereas no decrease in the number of beta(2)- and beta(3)-AR binding sites was observed after a 15 h SR 59119A treatment. 6. Neither PDE4 activity nor the beta(2)- and beta(3)-AR mRNA expression levels were affected by salbutamol or SR 59119A treatments. 7. Our results indicate that beta(3)-AR, but not beta(2)-AR, are resistant to the agonist-induced desensitisation. In our model, beta(2)-AR desensitisation is mediated by a decreased number of beta(2)-AR that was not explained by transcriptional regulation of the receptor.

UI MeSH Term Description Entries
D009215 Myometrium The smooth muscle coat of the uterus, which forms the main mass of the organ. Uterine Muscle,Muscle, Uterine,Muscles, Uterine,Uterine Muscles
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000318 Adrenergic beta-Agonists Drugs that selectively bind to and activate beta-adrenergic receptors. Adrenergic beta-Receptor Agonists,beta-Adrenergic Agonists,beta-Adrenergic Receptor Agonists,Adrenergic beta-Agonist,Adrenergic beta-Receptor Agonist,Betamimetics,Receptor Agonists, beta-Adrenergic,Receptors Agonists, Adrenergic beta,beta-Adrenergic Agonist,beta-Adrenergic Receptor Agonist,Adrenergic beta Agonist,Adrenergic beta Agonists,Adrenergic beta Receptor Agonist,Adrenergic beta Receptor Agonists,Agonist, Adrenergic beta-Receptor,Agonist, beta-Adrenergic,Agonist, beta-Adrenergic Receptor,Agonists, Adrenergic beta-Receptor,Agonists, beta-Adrenergic,Agonists, beta-Adrenergic Receptor,Receptor Agonist, beta-Adrenergic,Receptor Agonists, beta Adrenergic,beta Adrenergic Agonist,beta Adrenergic Agonists,beta Adrenergic Receptor Agonist,beta Adrenergic Receptor Agonists,beta-Agonist, Adrenergic,beta-Agonists, Adrenergic,beta-Receptor Agonist, Adrenergic,beta-Receptor Agonists, Adrenergic
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D058666 Adrenergic beta-2 Receptor Agonists Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. Adrenergic beta-2 Agonists,Adrenergic beta-2 Receptor Agonist,Adrenergic beta2-Agonists,Adrenergic beta 2 Agonists,Adrenergic beta 2 Receptor Agonist,Adrenergic beta 2 Receptor Agonists,Adrenergic beta2 Agonists,Agonists, Adrenergic beta-2,beta-2 Agonists, Adrenergic,beta2-Agonists, Adrenergic

Related Publications

C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization.
April 1993, Molecular pharmacology,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Beta 2-adrenoceptor agonist-induced down-regulation after short-term exposure.
September 1999, Journal of receptor and signal transduction research,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Desensitization of beta-1 and beta-2, but not beta-3, adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion.
April 1993, The Journal of pharmacology and experimental therapeutics,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Myometrial desensitization to continuous but not to intermittent beta-adrenergic agonist infusion in the sheep.
February 1986, American journal of obstetrics and gynecology,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
WITHDRAWN: Is nebivolol a beta(3)-adrenoceptor agonist?
February 2008, European journal of pharmacology,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Beta 2-adrenoceptor agonist-mediated inhibition of human airway smooth muscle cell proliferation: importance of the duration of beta 2-adrenoceptor stimulation.
June 1997, British journal of pharmacology,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Mechanisms of beta adrenoceptor desensitisation in the failing human heart.
October 1994, Cardiovascular research,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Role of beta ARK in long-term agonist-promoted desensitisation of the beta 2-adrenergic receptor.
March 1998, Cellular signalling,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
Sustained inhibition of antigen-induced histamine release from human lung by the beta 2-adrenoceptor agonist terbutaline.
July 1984, Allergy,
C Rouget, and M Breuiller-Fouché, and F J Mercier, and M J Leroy, and C Loustalot, and E Naline, and R Frydman, and T Croci, and E J Morcillo, and C Advenier, and M Bardou
The effect of pindolol on creatine kinase is not due to beta 2-adrenoceptor partial agonist activity.
June 1991, British journal of clinical pharmacology,
Copied contents to your clipboard!